The central obstacle is gastrointestinal toxicity. During the first infusion of zolbetuximab, many patients experience waves of nausea and vomiting that can be severe enough to frighten them away from subsequent cycles. In the pivotal phase III trials SPOTLIGHT and GLOW, which tested the antibody alongside mFOLFOX6 and CAPOX chemotherapy respectively, these early gastrointestinal events were the most frequent reason for dose delays and interruptions. Sagawa and colleagues contend that these symptoms are not random collateral damage but an expected consequence of the drug’s mechanism, arising when the antibody binds claudin 18.2 on healthy gastric mucosal cells as well as on tumor cells. That binding can trigger a distinctive, often transient gastritis, and the resulting inflammation of the stomach lining appears to feed directly into nausea, loss of appetite, and declining serum albumin levels. In their framing, nausea, vomiting, gastritis, anorexia, and hypoalbuminemia should be understood as interconnected on-target toxicities sharing a common origin in the stomach.

Some of the most intriguing evidence for this idea comes from endoscopy. In a study characterizing early-onset gastritis during zolbetuximab-containing chemotherapy, fully 89.7 percent of evaluated patients showed gastric inflammation on endoscopic examination within the early treatment period. Crucially, patients whose gastritis was diffuse rather than localized reported anorexia more frequently and experienced steeper declines in serum albumin. This pattern suggests a plausible physiological chain: the antibody injures the mucosa, the injured stomach generates nausea and suppresses appetite, reduced nutritional intake drives protein levels down, and the cumulative burden threatens both the patient’s condition and their willingness to continue therapy. Animal work offers supporting context, with ferret studies showing that gastric injury accompanies zolbetuximab-induced emesis and that certain antiemetics can mitigate both.

The Japanese experience adds a compelling and somewhat puzzling layer to the story. In a combined subgroup analysis of Japanese patients enrolled in SPOTLIGHT and GLOW, the progression-free survival benefit was markedly larger than in the overall trial populations, with a median of 20.53 months and a hazard ratio of 0.482, compared with hazard ratios of roughly 0.69 to 0.75 in the full cohorts. Japanese patients also tolerated the drug remarkably well: relative dose intensity exceeded 80 percent in 98.2 percent of Japanese participants versus 88.9 percent of non-Japanese patients, and not a single Japanese patient discontinued zolbetuximab permanently because of nausea or vomiting. The authors are careful to describe these findings as hypothesis-generating rather than proof. Higher cumulative drug exposure achieved through meticulous supportive care may partly explain the superior outcomes, but biological differences, population characteristics, and the intensive follow-up culture of Japanese oncology centers could all contribute, and disentangling these factors will require prospective study.

That said, a formal pharmacokinetic analysis gives the dose-delivery hypothesis real teeth. Researchers examining the clinical pharmacology of zolbetuximab found that patients with higher average concentrations of the antibody throughout treatment, a metric abbreviated Cave, lived longer without progression and longer overall. The antibody’s pharmacokinetics follow a predictable pattern in which tumor burden influences drug clearance, which complicates simple interpretation, but the association between sustained exposure and survival provides a mechanistic bridge between the supportive-care question and the efficacy question. If side effects force dose reductions and delays, drug levels fall, and the survival advantage may erode with them. The authors stress, however, that pharmacokinetic associations do not by themselves establish causality, and that only prospective trials testing supportive-care interventions against efficacy endpoints can settle the matter.

What makes the review practically valuable is its synthesis of the management strategies that have accumulated since the drug entered routine use. A RAND/UCLA modified Delphi panel brought together international experts to forge consensus guidance on preventing and treating zolbetuximab-related nausea and vomiting, and the recommendations converge on treating the first infusion as a high-emetic-risk event. That means aggressive prophylaxis with antiemetic regimens of the kind reserved for the most emetogenic chemotherapy, delivered before the antibody ever enters the vein. Beyond drugs, pragmatic institutional protocols have emerged describing stepwise escalation of the infusion rate, beginning slowly and accelerating as the first hours pass without symptoms, on the logic that the emetic reaction is concentrated at the start of exposure.

Real-world programs have validated this playbook. The Project VYLOY initiative in Japan assembled a practical framework for administration, and a retrospective supportive-care cohort study of a standardized administration protocol reported that a combination of high-risk antiemetic prophylaxis, gradual infusion-rate escalation, temporary interruption when symptoms appear, rescue antiemetics, intravenous hydration, and structured education of both patients and clinic staff can meaningfully improve tolerability and reduce interruptions in later cycles. The emphasis on education reflects a hard-won lesson from early clinical experience: patients who understand that first-infusion symptoms typically improve in subsequent cycles, and staff who know to slow or pause the infusion rather than abandon it, are far more likely to complete the intended course of therapy. Pharmacists, in this model, are not dispensers but protocol architects who tailor antiemetic combinations and manage drug interactions with the accompanying chemotherapy.

The multidisciplinary framing is where the review makes its most distinctive argument. Managing zolbetuximab toxicity, the authors contend, cannot be the oncologist’s job alone. Physicians must anticipate and grade the toxicities, nurses must recognize the earliest signs of infusion reactions and coach patients through the vulnerable first cycle, and pharmacists must design and adjust prophylaxis. Dietitians and nutrition support enter the picture when anorexia and hypoalbuminemia threaten nutritional status, because albumin decline is both a marker of deteriorating tolerance and potentially a driver of worse outcomes in its own right. The review’s integrated model treats the stomach as the shared battleground: the same target that makes the drug effective creates the toxicity, and the toxicity, if unmanaged, undermines the effectiveness. Breaking that loop requires the whole team, not a single specialist reacting to symptoms after they appear.

For patients and families, the practical message is one of cautious reassurance. The gastrointestinal side effects of zolbetuximab are real, frequently unpleasant, and concentrated at the start of treatment, but they are manageable with proactive planning, and the evidence suggests that patients who stay on therapy reap substantial benefits. The Japanese subgroup data, whatever their ultimate explanation, demonstrate that near-complete dose delivery is achievable without anyone abandoning the drug over nausea or vomiting. For oncology practices preparing to adopt zolbetuximab, the review functions as an implementation manual: premedicate aggressively, infuse slowly at first, hydrate, monitor albumin and nutritional intake, teach patients what to expect, and resist the temptation to stop a drug whose side effects usually soften with time.

What remains open is the scientific question lurking beneath the clinical one. If supportive care truly preserves drug exposure, and drug exposure truly drives survival, then the humble antiemetic infusion protocol becomes an efficacy intervention in disguise, and clinical trials should test it as such. Until those prospective studies are done, the authors’ distinction between established evidence and generated hypotheses stands: the toxicities are established, the management strategies are supported by growing real-world data, and the claim that better supportive care directly improves survival remains a well-grounded but unproven bet. It is a striking inversion of the usual narrative of cancer drug development, where breakthroughs are celebrated for their molecular cleverness. Zolbetuximab’s ultimate legacy may depend less on the elegance of its target than on whether the medical team in the infusion chair can keep a queasy patient coming back for the next dose.

Subject of Research: Multidisciplinary management of gastrointestinal and nutritional toxicities of zolbetuximab in first-line CLDN18.2-positive gastric cancer

Article Title: Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma

Article References: Making Zolbetuximab deliverable in practice: multidisciplinary management of nausea, vomiting, gastritis, and hypoalbuminemia in first-line CLDN18.2-positive, HER2-negative gastric/GEJ adenocarcinoma. (n.d.). https://doi.org/10.1007/s12032-026-03422-3

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03422-3

Keywords: zolbetuximab, claudin 18.2, gastric cancer, nausea, vomiting, gastritis, hypoalbuminemia, antiemetic prophylaxis, dose intensity, multidisciplinary care, SPOTLIGHT trial, GLOW trial

Acute gastroenteritis remains one of the most common reasons young children end up in emergency departments worldwide. The illness, usually viral, produces vomiting and diarrhea that can rapidly dehydrate a small body. The cornerstone of treatment is oral rehydration therapy, a carefully balanced solution of salts and sugars. The problem is that persistent vomiting often defeats oral rehydration before it can work, forcing clinicians toward intravenous lines, hospital admission, and prolonged distress. Ondansetron, a selective serotonin 5-HT3 receptor antagonist originally developed for chemotherapy-induced nausea, blocks the signaling pathway that triggers the vomiting reflex at the level of the gut and the brain’s vomiting center. Its adoption in pediatric emergency care has grown steadily, but the evidence base has needed updating.

The previous comprehensive meta-analysis on the question was published in 2020, and the research team identified three specific gaps it left open. It could not incorporate a subsequently published trial of multidose ondansetron given after hospital discharge, it did not evaluate the volume of oral rehydration solution children actually tolerated, and it did not formally explore sources of statistical heterogeneity through meta-regression. The new analysis, conducted and reported according to the PRISMA 2020 statement and guided by the AMSTAR 2 appraisal tool, set out to close those gaps. The researchers searched PubMed, CENTRAL, ScienceDirect, Google Scholar, and ClinicalTrials.gov through June 2026, and assessed risk of bias with the Cochrane RoB 2 tool and certainty of evidence with GRADE.

The headline results are striking in their consistency across measures of vomiting morbidity. Compared with placebo, ondansetron reduced the risk of ongoing vomiting by more than half, with a pooled risk ratio of 0.48. Children given the drug experienced on average 0.73 fewer vomiting episodes. Failure of oral rehydration therapy fell dramatically, with a risk ratio of 0.39, and the use of intravenous fluids dropped to 0.57 times the rate seen with placebo. Perhaps most tellingly for frontline practice, children who received ondansetron tolerated significantly more oral rehydration solution, a mean difference of nearly 48 milliliters more than placebo recipients. For a therapy whose entire purpose is to keep fluids going in by mouth rather than through a needle, that volume difference is clinically meaningful.

The picture darkens somewhat around the outcomes that matter most for health systems and families over longer horizons. The analysis found no significant difference between ondansetron and placebo in hospitalization rates, repeat healthcare visits, ongoing diarrhea, diarrheal episodes, or adverse events. Moreover, the hospitalization result proved fragile: it reached statistical significance only when a single large trial was omitted from the pooling, a sensitivity finding that undermines confidence in any true effect on admissions. Reassuringly for safety, the drug did not appear to worsen diarrhea, a concern sometimes raised because intestinal motility is partly serotonin-mediated. But the authors emphasize that the safety comparison rests on very few estimable comparisons and very few adverse events, meaning the analysis simply cannot rule out uncommon or delayed harms.

The durability of the antiemetic effect emerged as another key nuance. On subgroup analysis by follow-up duration, the benefit for ongoing vomiting was statistically significant through the first twenty-four hours but attenuated at forty-eight hours and beyond. This time-limited effect provides what the authors call a plausible rationale, though not direct evidence from the synthesis itself, for the extended multidose post-discharge regimen evaluated in the largest included trial. That trial, which the 2020 meta-analysis could not include, tested whether continued ondansetron after children left the emergency department could sustain the protection that a single dose evidently cannot. The updated evidence base now incorporates those findings, strengthening the argument that duration of action is a central design question rather than an afterthought.

Beneath the pooled estimates lies a more uncomfortable statistical story. The trials showed substantial heterogeneity, meaning their results varied far more than chance alone would predict. Exploratory meta-regression, introduced during revision and notably not specified in the registered protocol, suggested that the baseline proportion of male participants, baseline vomiting-episode frequency, and baseline diarrheal-episode frequency acted as study-level moderators of the effect on ongoing vomiting, while mean age did not. More concerning, Egger’s test indicated statistically significant funnel-plot asymmetry for both outcomes where publication bias could be assessed: ongoing vomiting, with a p-value of 0.03070, and number of vomiting episodes, with a p-value of 0.04627. Begg and Mazumdar’s rank correlation test was significant for neither, leaving the signal equivocal but sufficient for the authors to rate certainty of evidence as low for ongoing vomiting and very low for the number of vomiting episodes.

What does funnel-plot asymmetry mean in practical terms? Small trials with favorable results tend to be published more readily than small trials with null findings, so when the smaller studies in a meta-analysis cluster at one extreme of the funnel plot, it suggests the literature may be missing negative results. If so, the pooled effect sizes that look so impressive in the forest plots may overstate what a typical child would experience. The authors state this directly: the pooled magnitude of benefit on vomiting may be overstated. This kind of self-critical transparency is increasingly expected of high-quality systematic reviews, and it distinguishes this update from simpler aggregations that report point estimates without interrogating the shape of the evidence behind them.

The research team, which also included authors from Hawassa University in Ethiopia and Ad Diriyah Hospital in Riyadh, concludes that ondansetron significantly reduces vomiting morbidity in children with acute gastroenteritis, with no statistically significant difference versus placebo in adverse events or diarrhea. Their prescription for future research is precise: further randomized trials directly comparing single-dose and multidose regimens, particularly in high-burden, low-resource settings where gastroenteritis still kills, along with individual patient-data analyses that can resolve the heterogeneity that study-level meta-regression only glimpses. The review was registered prospectively on PROSPERO under identifier CRD420261447906, received no extramural funding, and is published open access. For emergency clinicians deciding whether a dose of ondansetron is worth offering a vomiting, dehydrated child, the accumulated evidence now points, with acknowledged caveats, toward yes.

Subject of Research: Efficacy and safety of ondansetron versus placebo for acute gastroenteritis-associated vomiting in children

Article Title: Updated evidence on efficacy and safety of ondansetron compared with placebo for acute gastroenteritis-associated vomiting in children: a systematic review and meta-analysis of randomized controlled trials

Article References: Althunayyan, B. S., Alhoushani, R. A., Alhesayani, L. M., Alsallal, S. A., Aldakhil, L. N., Alharbi, S. J., Alharbi, M. M., Aldaher, Y. J., Aljumah, Y. S., Alharbi, W. A., Yusuf, S. A., & Alrashidi, S. H. (2026). Updated evidence on efficacy and safety of ondansetron compared with placebo for acute gastroenteritis-associated vomiting in children: a systematic review and meta-analysis of randomized controlled trials. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07694-6

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07694-6

Keywords: ondansetron, acute gastroenteritis, vomiting, children, oral rehydration therapy, meta-analysis, randomized controlled trials, pediatrics, emergency care, intravenous fluids, publication bias, GRADE